Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong
· Delayed Price · Currency is HKD 33.05
-0.95 (-2.79%)
Apr 3, 2025, 4:08 PM HKT
Shanghai Henlius Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Revenue | 5,724 | 5,395 | 3,215 | 1,682 | 587.59 | Upgrade
|
| Revenue Growth (YoY) | 6.11% | 67.82% | 91.07% | 186.34% | 546.20% | Upgrade
|
| Cost of Revenue | 1,540 | 1,476 | 844.62 | 522.75 | 182.12 | Upgrade
|
| Gross Profit | 4,185 | 3,919 | 2,370 | 1,160 | 405.47 | Upgrade
|
| Selling, General & Admin | 2,288 | 2,138 | 1,403 | 800.87 | 436.29 | Upgrade
|
| Research & Development | 1,035 | 1,119 | 1,395 | 1,024 | 894.14 | Upgrade
|
| Operating Expenses | 3,318 | 3,287 | 2,999 | 1,825 | 1,330 | Upgrade
|
| Operating Income | 866.5 | 631.7 | -628.53 | -665.25 | -924.95 | Upgrade
|
| Interest Expense | -122.89 | -110.54 | -105.67 | -84.82 | -43.71 | Upgrade
|
| Interest & Investment Income | 21.7 | 8.15 | 3.57 | 2.69 | 7.4 | Upgrade
|
| Currency Exchange Gain (Loss) | 8.14 | -1.42 | 32.92 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 72.43 | 41.69 | 202.97 | -209.36 | -32.29 | Upgrade
|
| EBT Excluding Unusual Items | 845.88 | 569.58 | -494.73 | -956.74 | -993.54 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -199.15 | - | - | Upgrade
|
| Pretax Income | 845.88 | 569.58 | -693.89 | -956.74 | -993.54 | Upgrade
|
| Income Tax Expense | 25.41 | 23.56 | 1.37 | 27.31 | - | Upgrade
|
| Earnings From Continuing Operations | 820.47 | 546.02 | -695.26 | -984.05 | -993.54 | Upgrade
|
| Net Income | 820.47 | 546.02 | -695.26 | -984.05 | -993.54 | Upgrade
|
| Net Income to Common | 820.47 | 546.02 | -695.26 | -984.05 | -993.54 | Upgrade
|
| Net Income Growth | 50.26% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 543 | 543 | 542 | 539 | 530 | Upgrade
|
| Shares Outstanding (Diluted) | 543 | 543 | 542 | 539 | 530 | Upgrade
|
| Shares Change (YoY) | 0.02% | 0.25% | 0.59% | 1.75% | 6.52% | Upgrade
|
| EPS (Basic) | 1.51 | 1.01 | -1.28 | -1.83 | -1.88 | Upgrade
|
| EPS (Diluted) | 1.51 | 1.00 | -1.28 | -1.83 | -1.88 | Upgrade
|
| EPS Growth | 50.96% | - | - | - | - | Upgrade
|
| Free Cash Flow | - | 574.25 | 396.65 | -370.04 | -1,167 | Upgrade
|
| Free Cash Flow Per Share | - | 1.06 | 0.73 | -0.69 | -2.20 | Upgrade
|
| Gross Margin | 73.10% | 72.64% | 73.73% | 68.93% | 69.01% | Upgrade
|
| Operating Margin | 15.14% | 11.71% | -19.55% | -39.54% | -157.41% | Upgrade
|
| Profit Margin | 14.33% | 10.12% | -21.63% | -58.49% | -169.09% | Upgrade
|
| Free Cash Flow Margin | - | 10.64% | 12.34% | -21.99% | -198.54% | Upgrade
|
| EBITDA | 1,146 | 911.33 | -419.93 | -518.3 | -831.47 | Upgrade
|
| EBITDA Margin | 20.02% | 16.89% | -13.06% | -30.80% | -141.50% | Upgrade
|
| D&A For EBITDA | 279.63 | 279.63 | 208.6 | 146.95 | 93.49 | Upgrade
|
| EBIT | 866.5 | 631.7 | -628.53 | -665.25 | -924.95 | Upgrade
|
| EBIT Margin | 15.14% | 11.71% | -19.55% | -39.54% | -157.41% | Upgrade
|
| Effective Tax Rate | 3.00% | 4.14% | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.